CXCR7 modulator 2

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 ( CXCR7 ), with a K i of 13 nM. In Vitro CXCR7 modulator 2 (compound 18) demonstrates potent CXCR7-binding affinity (K i =13 nM) and β-arrestin activity (EC 50 =11 nM). CXCR7 modulator 2 also exhibits improved selectivity in the GPCR panel and an improved therapeutic index in the hERG patch-clamp assay in comparison with 11c. CXCR7 modulator 2 exhibits moderate to high in vitro turn over in both NADPH-supplemented mouse-liver microsomes (MLM, 93 μL/min/mg) and hepatocytes (28 μL/min per million cells), shows poor passive absorptive permeability in the MDCK II-permeability assay, and has good aqueous solubility. CXCR7 modulator 2 is rapidly absorbed with a mean maximal plasma concentration (C max ) of 682 ng/mL, which occurrs at 0.25 h (T max ). The corresponding mean area under the plasma-concentration-versus-time profile (AUC) is 740 ng/mL/h. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The administration of isoproterenol for 9 days leads to the development of cardiac fibrosis, as attested by the approximately 4-fold increase in collagen deposition relative to that in the control, which is detected by picrosirius-red staining. Treatment with CXCR7 modulator 2 results in a statistically significant reduction in cardiac fibrosis, thereby demonstrating the protective role of CXCR7 modulation with CXCR7 modulator 2 in an isoproterenol-induced cardiac injury . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:CXCR7 13 nM (Ki)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet